WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, debuted today with a ...
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Entasis Therapeutics Holdings Inc. has described mannan-binding lectin serine protease 2 (MASP2) and/or mannan-binding lectin serine protease 3 (MASP3) inhibitors reported to be useful for the ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced that it has entered into a ...
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace. Here we go again. Entasis Therapeutics has been struggling in the public marketplace. There is certainly ...
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results